secwatch.observer — SEC 8-K summary
======================================

Issuer:     Blueprint Medicines Corp (—)
CIK:        0001597264
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001558370-24-006451
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blueprint Medicines Q1 AYVAKIT revenue $92.5M, raises full-year guidance to $390-410M
--------------------------------------------------------------------------------

- AYVAKIT net product revenue $92.5M in Q1 2024, up >135% YoY from $39.1M.
- Full-year AYVAKIT revenue guidance raised to $390-410M from prior $360-390M.
- Net income of $89.1M includes a $173.7M non-cash debt extinguishment gain; prior year net loss $129.6M.
- Cash, cash equivalents and investments $735.6M as of March 31, 2024, down from $767.2M at year-end 2023.
- BLU-808 IND on track for Q2 2024; BLU-222 combination data to be presented at ASCO 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/0001558370-24-006451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/bpmc-20240502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer